Answers are grounded in this paper and cite their sources.
Background: C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are progressive kidney diseases driven by alternative complement pathway dysregulation. Although targeted complement inhibitors are promising, their comparative efficacy and safety remain uncertain. We evaluated these agents using Bayesian network meta-analysis. Methods: We reviewed randomized controlled trials evaluating complement inhibitors in C3G and IC-MPGN (2015-2025). The primary outcome was relative change in proteinuria at 6-months. Secondary outcomes included change in estimated glomerular filtration rate (eGFR), C3G histologic index, and adverse events at 6-months. Treatment effects were estimated using Bayesian models and ranked using surface under the cumulative ranking curve (SUCRA). Sensitivity analyses included random-effects models and 52-week extension data. Certainty was assessed using GRADE-NMA. The protocol was registered in PROSPERO (CRD420251250384). Results: Four trials, including 265 participants with trial-level mean ages 25-34 years (eligibility range, 12-80 years), evaluated pegcetacoplan, iptacopan, avacopan, and danicopan. Pegcetacoplan and iptacopan produced largest proteinuria reduction: pegcetacoplan -68.6% (95% credible interval [CrI], -83.2 to -54.0) and iptacopan -38.3% (95% CrI, -63.6 to -13.1) versus placebo (moderate certainty). In exploratory analyses, pegcetacoplan ranked highest (SUCRA 0.97), followed by iptacopan (0.66). Estimates for avacopan and danicopan were smaller, imprecise, and not statistically significant. Indirect comparisons were attenuated in sensitivity analyses, but hierarchy remained (low or very low certainty). Effects on eGFR were modest, without significant differences between active therapies. No therapy significantly improved C3G histologic index. Safety comparisons were limited by sparse events and short follow-up. Conclusions: Pegcetacoplan and iptacopan were associated with prompt proteinuria reduction versus placebo in C3G/IC-MPGN, while short-term kidney function improvements are expectedly modest. Although pegcetacoplan appeared more effective in the fixed-effect indirect analysis, between-treatment differences do not establish definitive superiority given their model-sensitivity, between trial differences and unavailability of long-term kidney outcomes. Longer-term follow-up, real-world comparative effectiveness data, and biomarker-driven studies are needed.
No takes yet. Share an insight, caveat, or question.
Khandelwal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: